{"id":"CU26101","slug":"gene-sequence-for-molecular--CU26101","source":{"id":"CU26101","dataset":"techtransfer","title":"Gene sequence for molecular diagnostics of interstitial cystitis/bladder pain syndrome (IC/BPS)","description_":"<p>This technology identifies a diagnostic DNA sequence of a gene implicated in Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS), which could be used to distinguish IC/BPS from other urological conditions, such as chronic urinary tract infections (UTIs).</p>\r\r<h2>Unmet Need: Reliable molecular diagnosis of interstitial cystitis/bladder pain syndrome (IC/BPS)</h2>\r\r<p>Interstitial cystitis/bladder pain syndrome (IC/BPS) is currently diagnosed through clinical evaluation and exclusion of other conditions, as its symptoms overlap with those of other urological disorders, such as chronic urinary tract infections (UTIs). The lack of validated molecular biomarkers complicates diagnosis, potentially leading to prolonged diagnostic uncertainty and unnecessary treatment. Reliable diagnostic tools are needed to distinguish IC/BPS from other bladder pathologies and enable more appropriate clinical management.</p>\r\r<h2>The Technology: DNA sequence for molecular diagnosis of IC/BPS</h2>\r\r<p>This technology identifies a DNA sequence of a gene implicated in interstitial cystitis/bladder pain syndrome (IC/BPS). The mutant sequence of this gene could potentially be used in molecular diagnostic assays to distinguish IC/BPS from other urological conditions with overlapping symptoms, including chronic urinary tract infections (UTIs). This approach may complement existing clinical diagnostic methods and support more accurate differential diagnosis of IC/BPS.</p>\r\r<h2>Applications:</h2>\r\r<ul>\r<li>Molecular diagnostic assays for IC/BPS</li>\r<li>Differential diagnosis of IC/BPS and chronic UTIs</li>\r<li>Patient stratification for IC/BPS research and clinical studies</li>\r<li>Potential companion diagnostics for IC/BPS therapies</li>\r</ul>\r\r<h2>Advantages:</h2>\r\r<ul>\r<li>Provides a DNA-based approach for IC/BPS diagnosis</li>\r<li>Differentiates IC/BPS from other urological disorders with overlapping symptoms</li>\r<li>Supports more appropriate patient management</li>\r<li>Enables potential genetic stratification of IC/BPS patients</li>\r</ul>\r\r<h2>Lead Inventor:</h2>\r\r<p><a href=\"https://www.pathology.columbia.edu/profile/jonathan-m-barasch-md\">Jonathan Barasch, MD, Ph.D.</a></p>\r\r<h2>Patent Information:</h2>\r\r<p>Patent Pending</p>\r\r<h2>Related Publications:</h2>\r\r<h2>Tech Ventures Reference:</h2>\r\r<ul>\r<li>Licensing Contact: <a href=\"mailto:techtransfer@columbia.edu\">Kristin Neuman</a></li>\r</ul>\r","tags":["DNA sequencing","Differential diagnosis","Interstitial cystitis","Mutation","Urinary tract infection"],"file_number":"CU26101","collections":[],"meta_description":"DNA-based diagnostic sequence for distinguishing IC/BPS from UTIs; enables precise molecular tests and patient stratification.","apriori_judge_output":"{\"scores\":{\"novelty\":3.0,\"potential_impact\":3.0,\"readiness\":2.0,\"scalability\":3.0,\"timeliness\":2.0},\"weighted_score\":2.8,\"risks\":[\"Genetic biomarker diagnostics face regulatory and clinical validation hurdles.\",\"May be limited by the specificity/sensitivity of the alleged DNA variant.\",\"Patent-pending status may not guarantee freedom-to-operate; potential overlap with existing assays.\"],\"one_sentence_take\":\"Moderate novelty and impact with early-readiness; regulatory/validation challenges and niche applicability temper investment potential.\"}","inventors":["Andrew Beenken","Atlas Khan","Jonathan M. Barasch","Krzysztof Kiryluk","Tian Shen"],"manager":"Kristin Neuman","depts":["Medicine"],"divs":["Columbia University Medical Center (CUMC)"],"date_released":"2026-10-30"},"highlight":{},"matched_queries":null,"score":0.0}